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Michael Nilsson11,12, Ola Hammarsten13, Staffan Nilsson14? and Henrik Zetterberg1,15?Abstract
Background: The transcription factor Nrf2, encoded by the NFE2L2 gene, is an important regulator of the cellular
protection against oxidative stress. Parkinson? s disease is a neurodegenerative disease highly associated with oxidative
stress. In a previously published study, we reported associations of NFE2L2 haplotypes with risk and age at onset of
idiopathic Parkinson? s disease in a Swedish discovery material and a Polish replication material. Here, we have extended
the replication study and performed meta-analyses including the Polish material and four new independent European
patient-control materials. Furthermore, all SNPs included in the haplotype windows were investigated individually for
associations with Parkinson? s disease in meta-analyses including all six materials.
Methods: Totally 1038 patients and 1600 control subjects were studied. Based on previous NFE2L2 haplotype
associations with Parkinson ? s disease, five NFE2L2 tag SNPs were genotyped by allelic discrimination and three
functional NFE2L2 promoter SNPs were genotyped by sequencing. The impact of individual SNPs and haplotypes
on risk and age at onset of Parkinson? s disease were investigated in each material individually and in meta-analyses of
the obtained results.
Results: Meta-analyses of NFE2L2 haplotypes showed association of haplotype GAGCAAAA, including the fully
functional promoter haplotype AGC, with decreased risk (OR = 0.8 per allele, p = 0.012) and delayed onset
(+1.1 years per allele, p = 0.048) of Parkinson ? s disease. These results support the previously observed protective
effect of this haplotype in the first study. Further, meta-analyses of the SNPs included in the haplotypes revealed
four NFE2L2 SNPs associated with age at onset of Parkinson? s disease (rs7557529 G > A, −1.0 years per allele, p = 0.042;
rs35652124 A > G, −1.1 years per allele, p = 0.045; rs2886161 A > G, −1.2 years per allele, p = 0.021; rs1806649 G >
A, +1.2 years per allele, p = 0.029). One of these (rs35652124) is a functional SNP located in the NFE2L2 promoter.
No individual SNP was associated with risk of Parkinson ? s disease.
Conclusion: Our results support the hypothesis that variation in the NFE2L2 gene, encoding a central protein in
the cellular protection against oxidative stress, may contribute to the pathogenesis of Parkinson ? s disease.
Functional studies are now needed to explore these results further.
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Parkinson ? s disease (PD) is a neurodegenerative disease
affecting the central nervous system, resulting in motor
symptoms such as rigidity, slowness of movement, pos-
tural instability and a characteristic resting tremor. The
motor symptoms derive from a decrease in the neuro-
transmitter dopamine (DA), due to death of dopamin-
ergic (DAergic) neurons in the substantia nigra (SN).
Even though several PD-causing genes have been identi-
fied, the majority of PD patients have an idiopathic form
without known cause and the disease process may
involve a combination of genetic and environmental
factors (reviewed in [1]). PD pathogenesis is known to
involve oxidative stress and the SN seems to be espe-
cially vulnerable. Incomplete intracellular oxidation of
DA in the SN, favored by the presence of ferrous iron,
may result in the formation of reactive DA(semi)-qui-
nones, which together with decreased levels of reduced
glutathione and chronic inflammation adds to the oxida-
tive stress observed in the PD brain (reviewed in [2,3]).
Nuclear factor erythroid 2 (NF-E2) related factor 2
(Nrf2), a transcription factor encoded by the NF-E2-like
2 (NFE2L2) gene, has a key role in the cellular protec-
tion against oxidative and electrophilic insults [4]. In the
normal state, Nrf2 is kept largely inactive by its repres-
sor protein kelch-like ECH-associated protein 1 (Keap1)
[5], which targets Nrf2 for ubiquitin ligation and subse-
quent degradation by the proteasome [6,7]. When Nrf2
is activated by oxidative or electrophilic stress, it induces
transcription of a battery of cytoprotective genes by
binding to a specific region in their promoters ? the
antioxidant response element (ARE) [8,9]. Nrf2 can also
be activated by dietary factors, such as sulforaphane or
curcumin, and Nrf2-activating substances have been
used in a number of pre-clinical PD models to study the
effect of Nrf2 upregulation on PD progression with a
pharmacological perspective (reviewed in [10,11]. Inter-
estingly, one study has shown that an increased oxidative
stress observed in olfactory neurosphere-derived cells
from PD patients could be restored by activation of
Nrf2 with sulforaphane [12] and curcumin has been
shown to protect DAergic SH-SY5Y neurons from 6-
Hydroxydopamine toxicity [13]. Another study has
shown that upregulation of Nrf2 using potent synthetic
Nrf2 activators protects DAergic neurons from degen-
eration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine (MPTP) mouse model of PD [14].
Nrf2 is essential in regulation of the cellular redox
homeostasis, as it controls rate-limiting steps in the
neo-synthesis of glutathione [15], as well as the induc-
tion of the antioxidant and neuroprotective enzyme
heme oxygenase 1 (HO-1) [16,17]. Another protein
regulated by Nrf2 is the highly inducible NAD(P)H
dehydrogenase, quinone 1 (NQO1) [18]. Besides its broadgeneral antioxidant activity, NQO1 prevents toxic redox
cycling of DA-quinones through a two-electron reduction
into stable hydroquinones [19]. NQO1 has been found to
be expressed in the SN of PD patients but not in age-
matched control subjects [20], suggesting an increased
Nrf2 activity in the PD brain. Nrf2 nuclear translocation is
enhanced in the PD affected SN [21] and a recent study
showing an increased Nrf2 activity in neurons derived
from induced pluripotent stem cells (iPSCs) from PD
patients [22] indicates a role for Nrf2 activation in the
PD pathogenesis. Considering all this, it is feasible that
a decreased radical protection due to genetic variation in
the NFE2L2 gene could affect the pathogenesis of PD.
We previously reported that a haplotype in the NFE2L2
gene, GAAAA consisting of five tag single nucleotide
polymorphisms (SNPs), was associated with delayed age
at onset (AAO) in a Swedish discovery material and
with decreased risk of PD in an independent Polish rep-
lication material [23]. In the same study, investigation
of three functional SNPs in the human NFE2L2 pro-
moter, previously shown to influence Nrf2 protein ex-
pression [24,25], revealed that the protective haplotype
GAAAA was in linkage disequilibrium (LD) with the
promoter haplotype AGC, which is part of a fully func-
tional promoter [23].
Here, based on our previous NFE2L2 haplotype asso-
ciations with PD in the Swedish Gothenburg (PD-Goth)
discovery material, seven NFE2L2 haplotypes and one in-
dividual SNP were investigated for associations with risk
and/or AAO of idiopathic PD in meta-analyses including
five independent patient-control replication materials. Fur-
thermore, with an exploratory approach despite lack of
association with risk in our previous study, all genotyped
SNPs were also independently investigated in meta-
analyses including the PD-Goth discovery material.
Methods
Patient-control materials
In total, 2638 individuals (1038 PD patients and 1600
controls) were included in this study. Subjects originated
from six independent research centers in Europe: Italy,
Malta, Poland and Germany, as well as two independent
patient-control sets from Sweden: Gothenburg (PD-Goth)
and Link?ping (PD-Link).
PD-Goth
PD-Goth was the discovery material in our previous
study [23] and included 165 PD patients and 190 control
individuals. All participants were of Caucasian origin
and patients and control subjects were of similar age. The
patients were diagnosed according to the Parkinson ? s
Disease Society Brain Bank criteria for idiopathic PD,
except that presence of more than one relative with PD
was not considered a criterion for exclusion. PD patients
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mutations in the recognized PD-causing genes DJ-1,
Parkin, PINK1 and LRRK2 [26,27].
Italy
The Italian material included 329 PD patients and 450
control subjects. All participants were of Caucasian
origin and the patients were diagnosed according to
the Parkinson ? s Disease Society Brain Bank criteria for
idiopathic PD. The controls were unrelated subjects
originating from the same geographical area as the
patients and all underwent neurological examination
for exclusion of neurological diseases.
PD-Link
The PD-Link material included 195 PD patients and 379
control subjects collected as part of the Geoparkinson
Study [28]. Blood samples were collected from L-dopa
positive PD patients in southeast Sweden visiting the
Clinic from Geriatrics and Neurology, University Hospital
in Link?ping, Sweden. The pat ients were classified as
having Parkinson ? s disease or parkinsonism using the
United Kingdom Parkinson ? s Disease Society Brain Bank
clinical diagnostic criteria and a neurologist confirmed
the diagnosis at recruitment. Individuals with vascular
or drug-induced parkinsonism were excluded from the
study, as were those with dementia. In this study, only
samples from patients with confirmed PD were used. The
controls were unrelated Swedish subjects randomly col-
lected from the normal population in southeast Sweden,
the same study base as the patients. The patient and
control groups were frequency-matched by age and sex.
Malta
The Malta material included 101 PD patients and 313 con-
trol subjects collected as part of the Geoparkinson Study
[28]. All participants were of Caucasian (Maltese) origin.
The patients were classified as having Parkinson? s disease
or parkinsonism using the United Kingdom Parkinson? s
Disease Society Brain Bank clinical diagnostic criteria. In
this study, only samples from patients with confirmed PD
were used. The controls were from the community or from
out-patients at St Luke? s Hospital, G ?Mangia, Malta. They
were group-matched to the patients by age and sex.
Poland
The Polish material was the replication material in our
previous study. It included 192 PD patients and 192 con-
trol subjects. All participants were of Caucasian origin
from the same geographic area, and were matched by sex.
Age at sampling (AAS) was significantly higher in the
control subjects than in the PD patients (to minimize the
risk of PD development in the controls later in life). The
patients fulfilled the Parkinson ? s Disease Society BrainBank criteria for idiopathic PD except for the presence
of more than one relative with PD, i.e. all patients with a
family history of PD were excluded from the study.
Germany
The German material included 56 PD patients and 76
control subjects. All participants were of Caucasian
origin and were matched by age and sex. PD was diag-
nosed by movement disorders specialists according to
the Parkinson ? s Disease Society Brain Bank criteria for
idiopathic PD. The controls were also personally examined
and free of any symptoms or signs suggestive of PD.
All materials contained information regarding sex and
AAS of patients and control subjects, and AAO of pa-
tients (i.e. age at diagnosis (AAD) for Germany, Malta
and PD-Link; and age at first symptom (AAFS) for PD-
Goth, Poland and Italy). Some materials also included
information on family history (FH; one or more 1st de-
gree family member(s) with PD) and smoking status.
Demographics are summarized in Table 1.
SNP selection
Selection of common SNP genotyping data covering
NFE2L2 for the European material CEU (Utah residents
with ancestry from Northern and Western Europe) were
performed when designing our previous study [23]. In
brief, SNP genotyping data was downloaded from the
International Haplotype Mapping Project web site (www.
hapmap.org) [29] and processed using the Haploview
software [30]. LD blocks were constructed according to
Gabriel et al. [31] and tag SNPs assigned using the tag-
ger function [30]. A minor allele frequency of ≥ 5% and
pair-wise tagging with a minimum r2 of 0.80 were ap-
plied to capture the common SNPs within the block
covering the NFE2L2 gene. In the same study promoter
SNPs were chosen due to their reported functional effect
on Nrf2 transcription [24,25]. The analyzed SNPs, in-
cluded in the haplotype window previously associated
with PD [23], were: five tag SNPs (rs7557529, rs2886161,
rs1806649, rs2001350 and rs10183914, here SNPs 2 ? 6)
and three functional promoter SNPs [24,25] (rs35652124,
rs6706649 and rs6721961, here SNPs P1 ? P3 [23]),
(Figure 1, Table 2).
Tag SNP genotyping and promoter sequencing
A detailed description of tag SNP genotyping and
sequencing of promoter SNPs is provided in our previ-
ous study [23]. In brief, all SNPs were genotyped using
genomic DNA extracted from blood. All tag SNPs were
genotyped using TaqMan Allelic Discrimination [32]
with TaqMan? Pre-Designed SNP genotyping assays
or TaqMan? Custom Made SNP genotyping assays
(Applied Biosystems, Foster City, CA, USA). The pro-
moter SNPs were genotyped by sequencing, amplifying
Table 1 Demographic characteristics of PD patients and control subjects
Parameter Sweden PD-Goth1 Italy Sweden PD-Link
PD Control p-value PD Control p-value PD Control p-value
N 165 190 ? 329 450 ? 195 379 ?
Sex (Male) 94 (57.0) 70 (36.8) <0.001 205 (62.3) 179 (39.8) <0.001 121 (62.1) 187 (49.3) 0.0043
AAS (years) 68.2 ? 8.8 69.1 ? 9.3 0.698 66.5 ? 9.2 57.0 ? 17.4 <0.001 71.4 ? 8.7 67.5 ? 9.7 <0.001 3
AAO2 (years) 59.0 ? 10.2 ? ? 60.1 ? 10.1 ? ? 63.6 ? 10.0 ? ?
N = 164 N = 328
FH 15 (9.3) 9 (4.8) 0.096 24 (7.3) ni ni 14 (7.2) 15 (4.0) 0.095
N = 162 N = 189
Current smoker 9 (8.7) 13 (8.3) 0.897 17 (8.2) ni ni 9 (4.6) 56 (14.8) <0.001
N = 208 N = 194
Ever smoked 38 (36.9) 81 (51.6) 0.020 77 (37.0) ni ni 63 (32.5) 183 (48.3) <0.001
N = 208 N = 194
Parameter Malta Poland Germany
PD Control p-value PD Control p-value PD Control p-value
N 101 313 ? 192 192 ? 56 76 ?
Sex (Male) 63 (62.4) 197 (62.9) 0.9193 117 (60.9) 117 (60.9) 1.0003 33 (58.9) 34 (44.7) 0.1073
AAS (years) 71.3 ? 10.0 72.7 ? 10.0 0.176 3 63.7 ? 10.9 72.9 ? 9.9 <0.001 4 66.0 ? 11.9 57.8 ? 10.8 <0.001 3
AAO1 (years) 64.1 ? 11.6 ? ? 55.2 ? 10.9 ? ? 58.7 ? 12.5 ? ?
N = 76 N = 54
FH 13 (12.9) 8 (2.6) <0.001 ni ni ni ni ni ni
Current smoker 3 (3.0) 25 (8.1) 0.076 ni ni ni ni ni ni
N = 308
Ever smoked 31 (30.7) 149 (47.6) 0.003 ni ni ni ni ni ni
Data are presented as absolute numbers (%) or mean ? SD. p-values were calculated with Pearson χ2-test for categorical parameters and Mann ? Whitney U test for
continuous parameters. AAS: age at sampling; AAO: age at onset; AAFS: age at first symptom; AAD: age at diagnosis; ni: no information available. FH: family history
(one or more 1st degree family member(s) with PD). N-numbers are shown if data was not available for all subjects in the analysis.
1Discovery material on which the replication analyses in this study are based.
2AAO is: AAFS for Italy, PD-Goth and Poland; AAD for Germany, Malta and PD-Link.
3The results are expected to be similar between the groups due to the applied matching in the original study design. Significant p-values are likely a result of not
including all samples from the original studies.
4This result is expected due to the original study design.
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primer 5? -GACCACTCTCCGACCTAAAGG-3? , reverse
primer 5? -CGAGATAAAGAGTTGTTTGCGAA-3? , an-
nealing temperature 59? C and 34 cycles on a PTC-200
ThermalCycler (Biorad, Hercules, CA, USA)). Purification
of the PCR product was performed with an Illustra? GFX?
PCR Purification Kit (GE Healthcare, Little Chalfont,
Buckinghamshire, UK). Sequence reactions were per-
formed using BigDye v3.1 (Applied Biosystems, Forster
City, CA, USA) and analyzed on an ABI PRISM 3100
Automated Sequencer (Applied Biosystems, Forster
City, CA, USA). Sequence data were analyzed with the
DNASTAR SeqMan? software (DNASTAR Inc., Madi-
son, WI, USA).
Statistical analyses
Demographic statistics were performed with SYSTAT11
(SYSTAT Software GmbH, Erkrath, Germany). Pearsonχ2-statistics were used for sex, FH and smoking history;
and Mann ? Whitney U test for AAS.
Genetic association analyses were performed using
HelixTree 6.3 (Golden Helix, Bozeman, MT, USA). All tag
SNPs were analyzed for deviation from Hardy? Weinberg
equilibrium. Based on the significant results in the
PD-Goth material [23], haplotypes were analyzed for
associations with PD (GAAAA, GAGGG and GAAAG
in the haplotype window consisting of tag SNPs 2 ? 6,
AGC in the window consisting of promoter SNPs 1 ? 3
and GAGCAAAA, GAGAAGGG and GAGCAAAG in
the window consisting of all eight SNPs combined, see
Figure 1 and Table 2 for SNP overview). A detailed de-
scription of how the haplotype windows were identified
is given in our previous study [23], where the identified
windows were corrected using permutations tests with
10 000 permutations and pc-values of ≤ 0.05 were con-
sidered statistically significant.
Figure 1 Schematic NFE2L2 gene positions of the studied SNPs
and their LD-patterns, showing r2-values as 100r2.
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(after correction for unequal sample sizes) and a desired
power of 80%, we can detect standardized differences
down to approximately 0.13 in this study [33], which
means that all the detected significances in risk and
AAO reported in our previous paper [23] can be de-
tected here at the applied significance level of 0.05.
SNP and haplotype associations were analyzed using
logistic or linear haplotype regression, where each haplo-
type was analyzed individually relative to all the other
haplotypes together. Sex was the only covariate available
in all materials. In order to maximize sample size and
power of the analyses and to make the results compar-
able between the independent materials, only sex was in-
cluded as covariate in our model (except for risk of PDTable 2 Overview of the studied SNPs
SNP rs-ID Genome position Alleles d >
NFE2L2 Chr:2(−)
2 rs7557529 177843343 G > A
P1 rs35652124 177838319 A > G
P2 rs6706649 177838317 G > A
P3 rs6721961 177838283 C > A
3 rs2886161 177836085 A > G
4 rs1806649 177826398 G > A
5 rs2001350 177808671 A > G
6 rs10183914 177805912 G > A
The SNPs analyzed in the study are numbered according to gene location in refere
Genome positions were obtained from the CEU population of the HapMap Genome
sequence of the gene.
1See reference [25].
2See reference [23].in the Polish material where the number of males and
females were identical in the patient and control
groups). However, when data was available and statisti-
cally relevant (see our previous study [23] for a detailed
description of how statistically relevant covariates were
selected), the effects of sex, FH and smoking habits were
evaluated in the meta-analyses to assure that exclusion
of covariates did not affect the outcomes. Haplotype fre-
quencies were estimated in each material individually
using the EM algorithm [34] allowing imputation to
compensate for missing genotypes.
Meta-analyses were performed using inverse-variance
weighting. In attempts to replicate our previously ob-
served associations, the five replication materials were
analyzed for associations of NFE2L2 with PD risk and
AAO. One-sided p-values ≤ 0.05 were considered statis-
tically significant. In the exploratory meta-analyses for
individual SNP associations with PD risk and AAO, all
six materials were included in the analyses. Two-sided
p-values ≤ 0.05 were considered statistically significant.Ethics
The study was approved by ethics committees in each
respective country (Sweden Gothenburg: the regional
ethics committee at University of Gothenburg, Sweden;
Italy: the ethical committee at the University Hospital
Mater Domini, Catanzaro, Italy; Sweden Link?ping: the
regional ethics committee at University of Link?ping,
Sweden; Malta: the research ethics committee at the
University of Malta, Malta; Poland: the ethics committee
of the Pomeranian Medical University, Szczecin, Poland;
Germany: the ethics committee of the University of
L?beck). This study was in compliance with the Helsinki
Declaration of 1975 and written informed consent was
obtained from all participants.D Gene location SNP type Taqman assay
5′-region ? C__436313_10
Promoter (−653) Regulatory1 Sequencing2
Promoter (−651) Regulatory1 Sequencing2
Promoter (−617) Regulatory1 Sequencing2
Intron 1 ? C__351881_10
Intron 1 ? C_11634983_10
Intron 1 ? C_11634985_10
Intron 3 ? C__157561_10
nce [23]; SNPs 2 ? 6 are tag SNPs; SNPs P1 ? P3 are functional promoter SNPs.
Browser (Phase 1 & 2 full dataset). Alleles are given according to the sense
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Demographics
PD-Goth: Patients and control subjects were similar in
age, FH and current smoking status, but differed signifi-
cantly in the distributions of sex and ever-smoker status.
Italy: Patients and control subjects differed significantly
in AAS and sex. No information was available regarding
FH or smoking habits for the control subjects. PD-Link:
Patients and control subjects did not differ with respect to
FH, but differed significantly in AAS, sex and smoking
status. Malta: Patients and control subjects were similar
in AAS, sex and current-smoker status, but differed
significantly with respect to FH and ever-smoker status.
Poland: Patients and control subjects were matched in
sex, but differed significantly in AAS due to the study
design. No information was available regarding PD FH
or smoking habits for either PD patients or control
subjects. Germany: Patients and control subjects were
similar regarding sex frequencies, but differed signifi-
cantly in AAS. No information was available regarding
PD FH or smoking habits for either PD patients or
control subjects.
In general, all centers had a higher percentage of males
relative to females amongst the patients (57.0 ? 62.4%).
Amongst the controls there was a wider range (36.8 ?
62.9%) due to different study designs. Similarly, the aver-
age AAS was more similar between the patient groups
(63.7 ? 71.4 years) than between the control groups
(57.0 ? 72.9 years). The Polish material stood out, since
the controls were older than the patients as a result of
the study design. The average AAO varied between 55.2
and 64.1 years and the average time from AAO until
AAS ranged from 6.4 to 9.2 years between the different
patient groups. Where data was provided, FH of PD was
always more common in the patient groups than in the
controls, though this difference did not always reach stat-
istical significance. As expected, smoking (ever smokers)
were more common in all patient groups than in the con-
trol groups, whenever data was available. All demograph-
ics are given in Table 1. Frequencies for the studied
NFE2L2 SNPs and haplotypes in patients and controls
are summarized in Additional file 1: Table S1 and
Additional file 2: Table S2, respectively.
Tag SNP genotyping
None of the studied SNPs had a Bonferroni-corrected
Hardy-Weinberg equilibrium p-value of < 0.001. The over-
all call rate was > 95%.
Haplotype associations
In accordance with the findings in the first study, meta-
analyses of NFE2L2 haplotypes including five independent
replication patient-control materials showed a protective
effect of the two haplotypes GAGCAAAA and GAAAAon PD. Haplotype GAGCAAAA, consisting of the five tag
SNPs and the three functional promoter SNPs (SNPs 2,
P1, P2, P3, 3, 4 ,5 and 6 according to gene direction, for rs
numbers see Table 2), was associated with both decreased
risk (OR = 0.8 per allele, p = 0.012) (Table 3, Figure 2A)
and later PD onset (+1.1 years per allele, p = 0.048)
(Table 4, Figure 2B). Haplotype GAAAA, consisting of tag
SNPs 2 ? 6 only, was associated with later PD onset
(+1.3 years per allele, p = 0.024) (Table 4) and showed a
tendency towards association with decreased PD risk
(OR = 0.9 per allele, p = 0.052) (Table 3).
None of the haplotypes GAGAAGGG, GAGGG, GAG-
CAAAG or GAAAG in the same two windows, all asso-
ciated with increased risk in the PD-Goth material in
the first study, was significantly associated with PD in the
meta-analyses. The promoter haplotype AGC alone was
not associated with PD in meta-analysis (Tables 3 and 4).
Individual SNP associations
Our previous protective association of the A allele of tag
SNP 6 (rs10183914) in the PD-Goth discovery study [23]
could not be replicated in the meta-analysis including the
five replication materials (+0.3 year per A allele, p = 0.23).
Exploratory meta-analyses of NFE2L2 individual SNPs,
including all six materials, showed no significant associa-
tions with risk of PD (Table 5).
Exploratory meta-analyses of NFE2L2 individual SNPs
with AAO, including all six materials, showed associations
with four SNPs; tag SNP 2 (rs7557529, ? 1.0 year per
A allele, p = 0.042), promoter SNP 1 (rs35652124, ? 1.1 year
per G allele, p = 0.045), tag SNP 3 (rs2886161, ? 1.2 year
per G allele, p = 0.021) and tag SNP 4 (rs1806649, +1.2
year per A allele, p = 0.029) (Table 6).
Discussion
Since oxidative stress is implicated in the pathogenesis
of PD [2,3] and Nrf2 is a central protein in the cellular
defense against oxidative stress, genetic variation affect-
ing the efficiency of Nrf2 could contribute to the disease.
Here, based on the previous results from our group [23],
we performed meta-analyses on five independent patient-
control materials to investigate the effects of seven haplo-
types in the Nrf2-encoding gene NFE2L2 on risk and
AAO of PD. In addition, the included SNPs were analyzed
individually in exploratory meta-analyses including the
PD-Goth discovery material. To our knowledge, with 1038
PD patients and 1600 control subjects included, this is the
most extensive attempt yet to investigate the impact of
genetic variation in NFE2L2 on PD risk and AAO.
Meta-analyses of three NFE2L2 haplotypes containing
five consecutive tag SNPs and three functional promoter
SNPs showed association of haplotype GAGCAAAA
with both decreased risk and later onset of PD (Tables 3
and 4, Figure 2). This supports our previously observed
Table 3 Replication of haplotype associations with risk of PD
Sweden PD-Goth Italy Sweden PD-Link Malta Poland Germany Meta-analysis2
SNP1 Haplotypes OR/allele (CI) OR/allele (CI) OR/allele (CI) OR/allele (CI) OR/allele (CI) OR/allele (CI) OR/allele (CI) p-value
2, 3, 4, 5, 6 GAAAA 0.8 (0.5 ? 1.1) 1.1 (0.9 ? 1.5) 0.9 (0.7 ? 1.2) 0.8 (0.6 ? 1.3) 0.7 (0.5 ? 0.9) 0.7 (0.4 ? 1.3) 0.88 (0.76 ? 1.03) 0.052
GAGGG 2.1 (1.2 ? 3.8) 1.2 (0.8 ? 1.7) 0.9 (0.5 ? 1.3) 0.7 (0.4 ? 1.3) 1.0 (0.6 ? 1.6) 1.1 (0.5 ? 2.5) 1.00 (0.81 ? 1.24) 0.50
GAAAG 2.8 (1.0 ? 7.7) 2.8 (1.1 ? 6.8) 0.4 (0.1 ? 1.2) 0.0 (0.0 ? 2.9 ? 10 18) 0.5 (0.2 ? 1.7) 0.0 (0.0 ? 21.6) 0.98 (0.54 ? 1.77) 0.53
P1, P2, P3 AGC 1.0 (0.7 ? 1.3) 1.1 (0.9 ? 1.3) 0.8 (0.6 ? 1.1) 1.0 (0.7 ? 1.3) 0.8 (0.6 ? 1.0) 0.9 (0.5 ? 1.5) 0.92 (0.81 ? 1.04) 0.09
2, P1, P2, P3, 3, 4, 5, 6 GAGCAAAA 0.8 (0.6 ? 1.1) 1.1 (0.9 ? 1.5) 0.9 (0.7 ? 1.2) 0.8 (0.6 ? 1.3) 0.5 (0.3 ? 0.7) 0.7 (0.4 ? 1.3) 0.84 (0.72 ? 0.98) 0.012
GAGAAGGG 2.4 (1.3 ? 4.5) 1.2 (0.9 ? 1.8) 0.9 (0.6 ? 1.4) 0.8 (0.4 ? 1.4) 0.6 (0.3 ? 1.0) 1.1 (0.5 ? 2.5) 0.95 (0.76 ? 1.18) 0.68
GAGCAAAG 2.9 (1.0 ? 8.4) 2.8 (1.1 ? 6.8) 0.4 (0.1 ? 1.2) 0.0 (0.0 ? 3.3 ? 10 36) 0.4 (0.1 ? 1.5) 0.0 (0.0 ? 29.2) 0.95 (0.52 ? 1.72) 0.57
Odds ratios (OR) are presented as absolute numbers (95% CI). Sex was used as covariate for all materials except for Poland, where the number of males and females are identical in patients and controls. Statistically
significant p-values are highlighted in bold.
1For SNP locations see Figure 1 and Table 2.
2The meta-analysis was calculated using inverse-variance weighting of effects with one-sided p-values and included all materials except Sweden PD-Goth, since it is the discovery material on which the haplotype
selection was based.
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Figure 2 Forest plot showing the NFE2L2 haplotype GAGCAAAA
associations with decreased risk (A) and later onset (B) of PD
in meta-analysis including the five replication materials: Italy,
Sweden PD-Link, Malta, Poland and Germany (filled squares).
The previous finding from the Swedish PD-Goth discovery study is also
shown (empty squares), though the material was not included in the
meta-analysis. The areas of the squares are proportional to the
meta-analysis weights (inverse variance).
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with later onset of PD in the PD-Goth discovery material
and decreased risk of PD in the Polish replication ma-
terial in the first study [23]. In addition, meta-analyses
of the three previously associated NFE2L2 haplotypes
in the window including the five tag SNPs only (tag
SNPs 2 ? 6) showed association of haplotype GAAAA
with later onset of PD. This haplotype also had a
tendency towards association with decreased risk ofPD. Obviously, GAGCAAAA and GAAAA are highly
influenced by one another and should not be considered
separate haplotypes. The promoter haplotype AGC is in
LD with the PD-associated haplotype GAAAA (r2 = 0.4)
[23] and the PD-associated combined haplotype GAG-
CAAAA contains the fully functional promoter haplo-
type AGC [24,25]. This suggests that the associations
could be driven by genetic variation in the NFE2L2 pro-
moter. However, the fact that the promoter haplotype
AGC alone showed no association with PD in meta-
analysis indicates that other parts of the gene are
involved as well. This is also in accordance with a
previous study on a Taiwanese material, where none of
the NFE2L2 promoter haplotypes were associated with
PD [35].
Haplotypes GAGAAGGG, GAGGG, GAGCAAAG and
GAAAG in the same two haplotype windows were all
associated with increased risk of PD in the PD-Goth
discovery material, but none of the associations could
be replicated here. Likewise, the association of tag SNP
6 (rs10183914) with later PD onset in the PD-Goth dis-
covery study could not be replicated in meta-analysis.
In line with our previous results, individual exploratory
meta-analyses of the genotyped NFE2L2 SNPs on patient
and control subjects from six independent European cen-
ters showed no associations with risk of PD. However, in
this study four NFE2L2 SNPs were associated with AAO
of PD in the exploratory meta-analyses. The minor alleles
of tag SNP 2 (rs7557529), promoter SNP P1 (rs35652124)
and tag SNP 3 (rs2886161) were all associated with one
year earlier PD onset per allele. Tag SNP 3 of our study
was previously included in a multiple candidate gene
study, but was not significantly associated with PD [36].
Tag SNP 2 is in LD (r2 = 0.9) with SNP rs6726395 [23],
which was previously found to increase the risk of PD in
a first-tier, sib-pair whole-genome study of PD, though
the association was not replicated in the second-tier case?
control study [37]. The minor G allele of promoter SNP
P1 has been shown to significantly decrease Nrf2 protein
levels [24,25]. Tag SNP 2 and especially tag SNP 3 of
our study are both in LD with the minor G allele of P1
(r2 = 0.4 and r2 = 0.9, respectively) (Figure 1), which could
possibly explain the observed associations of these SNPs
with earlier PD onset in our study. The minor A allele of
tag SNP 4 (rs1806649) was instead protective and delayed
onset of PD with one year per allele in meta-analysis.
Consistent with the discussion above, this SNP was not
in LD with SNP P1 (r2 = 0.1). Activation of Nrf2 with
natural or synthetic substances have been shown to
reduce oxidative stress and neurodegeneration in differ-
ent PD models [10,11], which suggests that Nrf2 could
be a suitable target for pharmacological intervention of
PD. In this context, the associations of NFE2L2 variants
with AAO of PD are interesting.
Table 4 Replication of haplotype associations with AAO of PD
Sweden PD-Goth Italy Sweden PD-Link Malta Poland Germany Meta-analysis2
SNP1 Haplotypes Years/allele (CI) Years/allele (CI) Years/allele (CI) Years/allele (CI) Years/allele (CI) Years/allele (CI) Years/allele (CI) p-value
2, 3, 4, 5, 6 GAAAA +4.1 (+1.3 ? +6.8) +0.6 (−1.5 ? +2.6) +2.8 (+0.5 ? +5.1) −0.4 (−5.0 ? +4.3) +1.2 (−1.6 ? +4.0) −0.2 (−6.8 ? +6.5) +1.28 (−0.01 ? +2.54) 0.024
GAGGG −0.9 (−4.6 ? +32.8) −0.4 (−2.9 ? +2.2) +2.1 (−1.6 ? +6.0) +0.5 (−7.0 ? +8.1) −0.7 (−4.2 ? +2.8) +1.3 (−5.4 ? +8.0) +0.19 (−1.50 ? +1.89) 0.59
GAAAG −3.6 (−9.1 ? +2.0) −0.2 (−5.7 ? +5.4) +1.0 (−8.7 ? +10.7) +253.1 (−483.1 ? +989.3) −1.2 (−10.8 ? +8.4) −60.9 (−221.2 ? +99.3) −0.16 (−4.46 ? +4.14) 0.47
P1, P2, P3 AGC +1.4 (−0.7 ? +3.6) +0.8 (−0.8 ? +2.4) −0.1 (−2.1 ? +1.9) +0.3 (−3.1 ? +3.7) −0.0 (−2.2 ? +2.1) −1.6 (−6.2 ? +2.9) +0.22 (−0.79 ? +1.23) 0.33
2, P1, P2, P3,
3, 4, 5, 6
GAGCAAAA +3.8 (+1.1 ? +6.5) +0.7 (−1.4 ? +2.7) +2.6 (+0.3 ? +5.0) −0.4 (−5.0 ? +4.3) +0.4 (−2.8 ? +3.6) −0.7 (−7.2 ? +5.7) +1.10 (−0.20 ? +2.40) 0.048
GAGAAGGG −0.8 (−4.6 ? +2.9) −0.3 (−2.9 ? +2.2) +2.1 (−1.7 ? +6.0) −0.5 (−7.0 ? +8.0) +0.5 (−3.7 ? +4.8) +1.3 (−5.4 ? +8.0) +0.51 (−1.26 ? +2.28) 0.71
GAGCAAAG −3.0 (−8.6 ? +2.6) +0.2 (−5.4 ? +5.8) +0.8 (−9.1 ? +10.6) −2817.1 (−5873.3 ? +239.1) −0.6 (−11.4 ? +10.2) −134.6 (−321.2 ? +51.9) +0.09 (−4.35 ? +4.52) 0.52
Effects on AAO are given as absolute numbers (95% CI). Sex was used as covariate for all materials. Statistically significant p-values are highlighted in bold.
1For SNP locations see Figure 1 and Table 2.
2The meta-analysis was calculated using inverse-variance weighting of effects with one-sided p-values and included all materials except Sweden PD-Goth, since it is the discovery material on which the haplotype
selection was based.
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Table 5 Individual SNP associations with risk of PD
Sweden PD-Goth Italy Sweden PD-Link Malta Poland Germany Meta-analysis2
SNP1 Genotype OR/allele (CI) OR/allele (CI) OR/allele (CI) OR/allele (CI) OR/allele (CI) OR/allele (CI) OR/allele (CI) p-value
2 ? rs7557529 G > A 0.9 (0.7 ? 1.2) 0.8 (0.7 ? 1.0) 1.2 (1.0 ? 1.6) 1.5 (1.1 ? 2.0) 1.3 (1.0 ? 1.8) 1.0 (0.6 ? 1.7) 1.08 (0.96 ? 1.21) 0.18
P1 ? rs35652124 A > G 0.8 (0.6 ? 1.2) 0.7 (0.6 ? 0.9) 1.3 (1.0 ? 1.7) 0.9 (0.6 ? 1.3) 1.3 (1.0 ? 1.8) 1.1 (0.6 ? 1.8) 0.99 (0.87 ? 1.12) 0.86
P2 ? rs6706649 G > A 0.9 (0.6 ? 1.4) 1.3 (0.9 ? 1.8) 1.1 (0.7 ? 1.5) 1.6 (1.0 ? 2.4) 1.0 (0.7 ? 1.5) 0.9 (0.4 ? 2.0) 1.14 (0.96 ? 1.35) 0.14
P3 ? rs6721961 C > A 1.8 (1.1 ? 3.0) 1.1 (0.8 ? 1.5) 0.9 (0.6 ? 1.4) 0.7 (0.4 ? 1.1) 1.0 (0.7 ? 1.6) 1.3 (0.7 ? 2.6) 1.07 (0.90 ? 1.27) 0.45
3 ? rs2886161 A > G 0.8 (0.6 ? 1.2) 0.7 (0.5 ? 0.9) 1.3 (1.0 ? 1.7) 1.0 (0.7 ? 1.4) 1.3 (1.0 ? 1.8) 1.1 (0.6 ? 1.8) 0.98 (0.87 ? 1.12) 0.81
4 ? rs1806649 G > A 1.0 (0.7 ? 1.3) 1.2 (0.9 ? 1.5) 0.8 (0.6 ? 1.1) 0.8 (0.6 ? 1.2) 0.7 (0.5 ? 0.9) 0.7 (0.4 ? 1.2) 0.88 (0.77 ? 1.01) 0.07
5 ? rs2001350 A > G 2.0 (1.1 ? 3.6) 1.3 (1.0 ? 1.8) 0.9 (0.6 ? 1.3) 0.8 (0.4 ? 1.4) 0.9 (0.6 ? 1.4) 1.0 (0.5 ? 2.1) 1.10 (0.91 ? 1.34) 0.31
6 ? 10183914 G > A 0.8 (0.6 ? 1.2) 1.1 (0.9 ? 1.4) 0.8 (0.6 ? 1.1) 1.0 (0.7 ? 1.4) 0.8 (0.6 ? 1.1) 0.9 (0.6 ? 1.6) 0.93 (0.82 ? 1.05) 0.22
Odds ratios (OR) are given for the minor allele and presented as absolute numbers (95% CI). Sex was used as covariate for all materials except for Poland, where the number of males and females are identical in
patients and controls.
1For SNP locations see Figure 1 and Table 2.
2The meta-analysis was calculated using inverse-variance weighting of effects with two-sided p-values, including all six materials.
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Table 6 Individual SNP associations with AAO of PD
Sweden PD-Goth Italy Sweden PD-Link Malta Poland Germany Meta-analysis2
SNP1 Genotype Years/allele (CI) Years/allele (CI) Years/allele (CI) Years/allele (CI) Years/allele (CI) Years/allele (CI) Years/allele (CI) p-value
2 ? rs7557529 G > A −1.7 (−3.9 ? +0.6) −0.4 (−2.0 ? +1.3) −2.2 (−4.3 ? -0.1) −0.8 (−4.7 ? +3.1) −0.2 (−2.4 ? +2.0) −0.8 (−6.0 ? +4.3) −0.99 (−1.94 ? -0.03) 0.042
P1 ? rs35652124 A > G −2.1 (−4.5 ? +0.3) −1.3 (−3.3 ? +0.7) −1.8 (−4.1 ? +0.5) −1.6 (−5.8 ? +2.6) +0.2 (−2.0 ? +2.4) +2.8 (−2.3 ? +7.8) −1.07 (−2.12 ? -0.02) 0.045
P2 ? rs6706649 G > A +1.4 (−1.8 ? +4.7) +1.4 (−0.9 ? +3.8) +1.4 (−1.5 ? +4.2) −0.0 (−5.2 ? +5.2) −0.6 (−3.7 ? +2.5) −1.7 (−9.5 ? +6.0) +0.85 (−0.49 ? +2.19) 0.22
P3 ? rs6721961 C > A −1.5 (−5.0 ? +2.0) −0.7 (−2.7 ? +1.3) +2.1 (−1.4 ? +5.6) +2.7 (−3.2 ? +8.6) +0.3 (−2.8 ? +3.3) +0.0 (−6.0 ? +6.1) −0.81 (−2.03 ? +0.41) 0.19
3 ? rs2886161 A > G −2.4 (−4.8 ? -0.1) −1.4 (−3.4 ? +0.6) −2.0 (−4.3 ? +0.3) −1.5 (−5.6 ? +2.7) +0.0 (−2.2 ? +2.2) +2.7 (−2. 4 ? +7.8) −1.23 (−2.27 ? -0.18) 0.021
4 ? rs1806649 G > A +2.7 (+0.2 ? +5.1) +0.4 (−1.5 ? +2.4) +2.7 (+0.4 ? +4.9) −2.4 (−7.0 ? +2.1) +1.0 (−1.7 ? +3.7) −3.6 (−9.5 ? +2.3) +1.20 (+0.12 ? +2.28) 0.029
5 ? rs2001350 A > G −0.6 (−4.3 ? +3.0) −0.8 (−3.1 ? +1.6) +1.8 (−1.9 ? +5.6) +1.8 (−5.1 ? +8.8) −0.7 (−4.1 ? +2.8) +1.1 (−5.7 ? +7.8) −0.11 (−1.59 ? +1.37) 0.88
6 ? 10183914 G > A +3.7 (+1.3 ? +6.2) +0.3 (−1.3 ? +2.0) +1.5 (−0.6 ? +3.7) −0.4 (−4.2 ? +3.3) −0.1 (−2.4 ? +2.3) −1.4 (−6.2 ? +3.5) +0.95 (−0.04 ? +1.94) 0.06
Effects on AAO are given for the minor allele and presented as absolute numbers (95% CI). Sex was used as covariate for all materials. Statistically significant p-values are highlighted in bold.
1For SNP locations see Figure 1 and Table 2.
2The meta-analysis was calculated using inverse-variance weighting of effects with two-sided p-values, including all six materials.
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http://www.biomedcentral.com/1471-2350/15/131Though haplotype GAGCAAAA showed a trend towards
increased risk of PD in the Italian material when the mate-
rials were analyzed individually, this haplotype decreased
the risk of PD in meta-analysis (Table 3, Figure 2A).
Idiopathic PD is a multifactorial disease caused by several
risk genes, possibly in combination with environmental
factors. This may explain why the effect of a risk gene could
be more obvious in some materials than in others. Also,
study design as well as different genetic background in both
PD patients and controls could affect the outcome of a
multicenter study. Considering this, despite the relatively
small effects in the meta-analyses, the replicated associa-
tions between genetic variation in the NFE2L2 gene and
idiopathic PD are interesting and should be investigated
further in functional studies.
Conclusions
Meta-analyses including five independent patient-control
materials from different European centers confirmed pro-
tective effects of NFE2L2 haplotypes GAGCAAAA and
GAAAA against PD. In addition, exploratory meta-analyses
revealed four individual SNPs affecting the AAO of PD, in-
cluding a functional SNP located in the NFE2L2 promoter.
In summary, our data support the hypothesis that variation
in the Nrf2-encoding gene NFE2L2 may contribute to the
pathogenesis of idiopathic PD.
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